Kane Biotech (KNE) Stock Price, News & Analysis

Company Overview

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. The company is also developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; coactiv+ Antimicrobial Wound Rinse for use in acute and chronic wounds; coactiv+ Antimicrobial Wound Gel Spray for use in acute, chronic wounds, and first and second degree burns; and DispersinB Hydrogel for prosthetic joint infection. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

Key Stats

• Today's Range: C$0.04 to C$0.04
• 50-Day Range: C$0.04 to C$0.06
• 52-Week Range: C$0.04 to C$0.16
• Volume: 1,000 shs
• Average Volume: 74,061 shs
• Market Capitalization: C$6.05 million
• P/E Ratio: 1.05
• Dividend Yield: 3.08%
• Price Target: N/A
• Consensus Rating: N/A

KNE Stock Analysis - Frequently Asked Questions

How have KNE shares performed this year?

Kane Biotech's stock was trading at C$0.11 at the beginning of 2025. Since then, KNE shares have decreased by 61.8% and is now trading at C$0.04.

How do I buy shares of Kane Biotech?

Shares of KNE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Kane Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kane Biotech investors own include Mason Resources (LLG), Datametrex AI (DM) and Allstar Health Brands (ALST).

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: CVE:KNE
• CIK: N/A
• Web: www.kanebiotech.com
• Phone: +1-204-4531301
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C$0.04
• Trailing P/E Ratio: 1.05
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$6.03 million
• Net Margins: 423.52%
• Pretax Margin: N/A
• Return on Equity: -94.49%
• Return on Assets: -58.43%

Debt

• Debt-to-Equity Ratio: -331.42
• Current Ratio: 0.80
• Quick Ratio: 0.39

Sales & Book Value

• Annual Sales: C$1.42 million
• Price / Sales: 4.25
• Cash Flow: C$0.00 per share
• Price / Cash Flow: 8.50
• Book Value: C($0.01) per share
• Price / Book: -8.16

Miscellaneous

• Outstanding Shares: 144,060,190
• Free Float: N/A
• Market Cap: C$6.05 million
• Optionable: Not Optionable
• Beta: 0.52